Lung HeXeRT: Helium, Xenon MRI for NSCLC Patients | Recruiting
Lung HeXeRT: Helium, Xenon MRI for ... | Recruiting
Lung HeXeRT: Helium, Xenon MRI for NSCLC Patients
HeXeRT

Location not identified by Google services

Location data is sourced from multiple external providers and UKCTG is not responsible for and cannot guarantee the accuracy of data.

Medical Conditions
  • NSCLC
Primary Contact Details
Recruitment Status
Recruiting
Trial source and source ID number
NCT01859650
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Summary
The University of Sheffield is one of the leading centres in the world for basic and translational research with inhaled gas MRI, which provides lung images with unprecedented spatial and temporal resolution. Our previous work demonstrated that inhaled gas MRI can provide significant clinical information for lung cancer radiotherapy planning and post-treatment evaluation. Building upon this unique experience, a multidisciplinary team will conduct an inhaled gas and proton lung MRI study that will address two of the major clinical problems faced by lung cancer patients treated with radiotherapy.

1. Normal lung tissue is often damaged by the curative radiation dose. The investigators hypothesise that regional ventilation-perfusion lung function imaging with inhaled gas and proton MRI before and after treatment will help to lower the risk of radiation-induced lung injury and help to detect such damage at an early stage.

2. Identification of the extent of cancerous tissue is error-prone when planning treatment from CT images alone. The investigators hypothesise that advanced proton MRI techniques will improve the identification of tumour volume, which is critical to successfully targeting the radiation dose.

To achieve these goals, image acquisition and image processing methods will be tested with a study of 20 patients. Results from this study will make an important contribution to improving the treatment of lung disease which is one of the key research priorities of the NHS.
Research Details
    Sorry, this information is not available
Phase
N/A
Study Design
Sorry, this information is not available
Study Type
Observational
Intervention
Other : MR and CT imaging

Study Arm Groups : NSCLC patients undergoing RT

Intervention Type
See Interventions above
Primary Outcome Measures
    Percentage of ventilated lung measured using inhaled gas MRI; Change between pre treatment (average 10 days before start of treatment) and at 3 months post treatment
Secondary Outcome Measures
    Lung tumour volume measured using proton MRI; Change between pre-treatment (average 10 days before start of treatment) and at 3 months post treatment; Percentage of ventilated lung measured using CT; Change between pre-treatment (average of 10 days before start of treatment) and at 3 months post-treatment
Publication(s)
Sorry, this information is not available
Result Reports
Check availability of results on the Clinicaltrials.gov website
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Gender
All
Age Range
18 Years - N/A
Who Can Participate
Patients
Number of Participants
20
Participant Inclusion Criteria
    Inclusion Criteria:

    - Patients with an MDT diagnosis of NSCLC based on findings of positive histology, positive PET scan or growth on serial CT scan requiring CT planning for radiotherapy treatment

    - patients aged over 18

    - patients able to undergo MRI scanning.

    Exclusion Criteria:

    - patients with co-morbid conditions that exclude radiotherapy treatment

    - patients who are pregnant or women with child bearing potential

    - patients unable to give informed consent

    - patients who do not understand English sufficiently to read the patient information sheet, provide informed consent or converse with research staff without interpreters.
Participant Exclusion Criteria
This is in the inclusion criteria above
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Trial Location(s)
Sheffield
S10 2SJ
Trial Contact(s)
Primary Trial Contact
Matthew Q Hatton, FRCR, FRCP
Other Trial Contacts
Sorry, this information is not available
Countries Recruiting
United Kingdom
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Scientific Title
Lung HeXeRT: Advanced Proton, Hyperpolarised 3-helium and 129-xenon Magnetic Resonance Imaging for Lung Cancer Radiotherapy Planning and Evaluation
EudraCT Number
Not available for this trial
Funder(s)
  • University of Sheffield
  • Weston Park Hospital Cancer Charity
  • Sheffield Hospitals Charity
Other Study ID Numbers
STH17245
Sponsor(s)
Sheffield Teaching Hospitals NHS Foundation Trust
Key Dates

Recruitment Start Date

Dec 2014

Recruitment End Date

Dec 2018

Trial Start Date
Date Not Available
Trial End Date
Date Not Available
Date added to source

10 May 2013

Date updated in source

04 May 2017